# The Biotech Valuation Handbook: companion files

Julian R. Sterling. Companion page: julianrsterling.com/biotech-valuation

1. **Biotech_rNPV_Workbook.xlsx**: the eleven-tab model behind every Veltrana Therapeutics, Inc. figure in the book (valuation date January 1, 2027, horizon 2027 to 2050, USD millions): README, Inputs, VLT201_Revenue, VLT201_rNPV, VLT305, Deal_Marlowe, VLT410_Tree, SOTP, Sensitivities, Runway and Controls. Controls!C3 must read 0.
2. **rNPV_Drug_Asset_Model.xlsx**: a standalone single-asset rNPV model (probabilities by phase, patient funnel, launch curve, IRA price, loss of exclusivity, licence income), prefilled with VLT-201: its rNPV reads $71.09 million. Replace the blue cells with your own asset.

Blue cells are inputs, black cells are formulas, no circular references. Open the files in Excel and let them calculate. Education only, not investment advice; rules as read in November 2026. The company, its products and every figure are fictional.
